Paul Carter
Direktor/Vorstandsmitglied bei HUTCHMED (CHINA) LIMITED
Vermögen: 677 259 $ am 30.04.2024
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| John F. Donovan | M | - |
Concentric Analgesics, Inc.
 Concentric Analgesics, Inc. Packaged SoftwareTechnology Services Concentric Analgesics, Inc. develops novel, non-opioid therapeutics for the management of acute postsurgical and chronic osteoarthritis pain. The company was founded by John F. Donovan, Frank J. Bellizzi and Craig O. Husfeld in 2014 and is headquartered in San Francisco, CA. | 10 Jahre |
| Per Lundin | M | 41 |
Evox Therapeutics Ltd.
 Evox Therapeutics Ltd. BiotechnologyHealth Technology Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom. | 8 Jahre |
| Murray Stewart | M | 63 |
VectivBio AG
 VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 21 Jahre |
| Craig O. Husfeld | M | - |
Concentric Analgesics, Inc.
Concentric Analgesics, Inc. Packaged SoftwareTechnology Services Concentric Analgesics, Inc. develops novel, non-opioid therapeutics for the management of acute postsurgical and chronic osteoarthritis pain. The company was founded by John F. Donovan, Frank J. Bellizzi and Craig O. Husfeld in 2014 and is headquartered in San Francisco, CA. | 10 Jahre |
| Anthony Tennyson | M | - | 4 Jahre | |
| Jonathan Held | M | 38 | 4 Jahre | |
| Johannes G. C. P. Schikan | M | 66 |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 5 Jahre |
| John McHutchison | M | 66 |
Evox Therapeutics Ltd.
Evox Therapeutics Ltd. BiotechnologyHealth Technology Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom. | 13 Jahre |
| Edith Shih | F | 71 | 24 Jahre | |
| Sandipkumar S. Kapadia | M | 54 |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 4 Jahre |
| Chahra Khaoua Epouse Louafi | F | 53 |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 4 Jahre |
| Thomas Woiwode | M | 52 |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 5 Jahre |
| Frank J. Bellizzi | M | 58 |
Concentric Analgesics, Inc.
Concentric Analgesics, Inc. Packaged SoftwareTechnology Services Concentric Analgesics, Inc. develops novel, non-opioid therapeutics for the management of acute postsurgical and chronic osteoarthritis pain. The company was founded by John F. Donovan, Frank J. Bellizzi and Craig O. Husfeld in 2014 and is headquartered in San Francisco, CA. | 10 Jahre |
| Harpreet Singh-Jasuja | M | 50 | 24 Jahre | |
| Jeremy Charles Green | M | 49 | 6 Jahre | |
| Stephen P. Squinto | M | 67 |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 4 Jahre |
| Luca Santarelli | M | 55 |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 5 Jahre |
| Wei Guo Su | M | 66 | 19 Jahre | |
| Mark Lee | M | 46 | - | |
| Shu Kam Mok | M | 63 | 7 Jahre | |
| Matthew Wood | M | - |
Evox Therapeutics Ltd.
Evox Therapeutics Ltd. BiotechnologyHealth Technology Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom. | 8 Jahre |
| Steffen Walter | M | 47 | 4 Jahre | |
| James Ford | M | - | 29 Jahre | |
| John Papastergiou | M | - | - | |
| Gordo Whittaker | M | - | - | |
| Derek Belz | M | - | 2 Jahre | |
| George Scorsis | M | - | - | |
| Michael Atieh | M | 70 | 4 Jahre | |
| Stephen Page | M | - | - | |
| Bryan Reasons | M | 56 | 5 Jahre | |
| Thomas King | M | 69 |
Concentric Analgesics, Inc.
Concentric Analgesics, Inc. Packaged SoftwareTechnology Services Concentric Analgesics, Inc. develops novel, non-opioid therapeutics for the management of acute postsurgical and chronic osteoarthritis pain. The company was founded by John F. Donovan, Frank J. Bellizzi and Craig O. Husfeld in 2014 and is headquartered in San Francisco, CA. | 7 Jahre |
| Heather Mason | F | 63 | 4 Jahre | |
| Graeme Jack | M | 73 | 7 Jahre | |
| Chig Fung Cheng | M | 57 | 16 Jahre | |
| Dan Eldar | M | 70 | 8 Jahre | |
| Andrew Dickinson | M | 54 | 8 Jahre | |
| Edward Sturchio | M | - | 4 Jahre | |
| Miriam Meyer | M | - | 15 Jahre | |
| Ephraim Hofsäß | M | - | 5 Jahre | |
| Timothy Woodthorpe | M | - | 24 Jahre | |
| James Collins | M | - | - | |
| Yiling Cui | F | - | - | |
| Sarah Gordon-Wild | F | - |
Evox Therapeutics Ltd.
Evox Therapeutics Ltd. BiotechnologyHealth Technology Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom. | - |
| Christian Meyer | M | 56 |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | - |
| Amrit Nagpal | M | - |
Evox Therapeutics Ltd.
Evox Therapeutics Ltd. BiotechnologyHealth Technology Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom. | - |
| Roger K. Cady | M | - | 8 Jahre | |
| Jordan Silverstein | M | - | 5 Jahre | |
| Michael Leung | M | - | 24 Jahre | |
| Adam Stoten | M | - |
Evox Therapeutics Ltd.
Evox Therapeutics Ltd. BiotechnologyHealth Technology Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom. | 8 Jahre |
| Rainer Kramer | M | 60 | 12 Jahre | |
| May Wang | M | 60 | 14 Jahre | |
| Charles Nixon | M | 54 | 18 Jahre | |
| Jia Huey Cheng | F | 48 | - | |
| Naomi Junghae | F | - | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Mark Litton | M | 56 | 14 Jahre | |
| Randall Schatzman | M | 69 | 14 Jahre | |
| Alan Montgomery | M | 70 | 13 Jahre | |
| Mark Trudeau | M | 62 | 9 Jahre | |
| Paul Cleveland | M | 67 | - | |
| Matthew Harbaugh | M | 53 | 6 Jahre | |
| Christian Hogg | M | 58 | 16 Jahre | |
| Angus Russell | M | 68 | 8 Jahre | |
| Melissa Yeager | F | - | 10 Jahre | |
| Robert Azelby | M | 56 | 1 Jahre | |
| Kevin Chow | M | 54 | 7 Jahre | |
| Benjamin Sessa | M | - | - | |
| Christopher Huang | M | 72 | 11 Jahre | |
| Larry K. Benedict | M | 63 | 11 Jahre | |
| Peter Bisgaard | M | 50 | 3 Jahre | |
| Anne Michelle Whitaker | F | 56 | 4 Jahre | |
| Daniel A. Celentano | M | 72 | 1 Jahre | |
| Scott Applebaum | M | 57 | - | |
| David Walsey | M | - | - | |
| John Latham | M | 64 | 15 Jahre | |
| Riad El-Dada | M | 59 | 1 Jahre | |
| Wouter Joustra | M | 35 | 1 Jahre | |
| Carlos Paya | M | 65 | 3 Jahre | |
| Gordon Earle Moore | M | 95 | 17 Jahre | |
| Gary Bridger | M | 61 | 3 Jahre | |
| Paul Bisaro | M | 63 | 1 Jahre | |
| JoAnn Reed | F | 68 | 9 Jahre | |
| J. Carroll | M | 74 | 9 Jahre | |
| Eric Carter | M | 72 | 1 Jahre | |
| David Norton | M | 72 | 5 Jahre | |
| H. Culp | M | 60 | 9 Jahre | |
| Melvin Booth | M | 79 | 5 Jahre | |
| Kneeland Youngblood | M | 69 | 9 Jahre | |
| James Sulat | M | 73 | 1 Jahre | |
| Clay Siegall | M | 63 | 14 Jahre | |
| David Carlucci | M | 69 | 9 Jahre | |
| Robert Wilson | M | 81 | 11 Jahre | |
| John David Coombe | M | 79 | 5 Jahre | |
| Neal Goldman | M | 54 | 1 Jahre | |
| Stephen M. Dow | M | 68 | 13 Jahre | |
| Wendy Yarno | F | 69 | - | |
| Deepa Pakianathan | M | 59 | 6 Jahre | |
| Michael William Davis Howell | M | 76 | 11 Jahre | |
| Diane Gulyas | F | 67 | 5 Jahre | |
| Chi Keung To | M | 72 | 24 Jahre | |
| Patrick Malloy | M | - | - |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 26 | 26,00% |
| Irland | 19 | 19,00% |
| Hong Kong | 16 | 16,00% |
| Vereinigtes Königreich | 13 | 13,00% |
| Schweiz | 11 | 11,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Paul Carter
- Persönliches Netzwerk
